I'm essentially with Vin and 4Seasons on this one. The review can work both ways. It prudently protects Teva's bottom line but is also a great opportunity to fast track. What I am more sceptical about is the time-frame. I'd be surprised if the review takes place as early as 1st quarter 2014 as I'd imagine they would need to follow up on these early patients for at least 6 or 12 months. This is still "early" as a full Phase III normally takes about 3 years. I, of course, hope I'm wrong and that an even earlier review shows such compelling evidence of efficacy that the road to market is fast-tracked but I think we should avoid seeing a delay as bad news.
teva q3 earnings call (q&a session)., page-5
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |